Pharmacokinetic (PK), Pharmacodynamic (PD), and Safety Study of Subcutaneously Administered Humalog® With and Without Recombinant Human Hyaluronidase (rHuPH20)and Humulin-R® With and Without rHuPH20

NCT00705536 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

26

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus

Interventions

DRUG: Humalog
DRUG: Humulin-R
DRUG: Recombinant human hyaluronidase PH20 (rHuPH20)

Sponsor

Halozyme Therapeutics